undamentalytics Newsletter
Sign in

Caribou Biosciences, Inc. balance sheet

At the end of fiscal 2025, Caribou Biosciences, Inc. had total assets of $175m, total liabilities of $53.2m and shareholders' equity of $122m. It held $12.4m in cash against $0 of debt: net cash of $12.4m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents41162405851161226
Receivables—0100000
Total current assets—24391260339219145117
Total assets—36442374432313175143
Accounts payable—3413263
Deferred revenue (current)—09103320
Total current liabilities—12262828312518
Total debt00000000
Total liabilities—18557364605345
Shareholders' equity7−2338830136825312298
Non-controlling interests and other (assets − liabilities − equity)—41——————
Net debt (negative = net cash)−41−16−240−58−51−16−12−26
Shares outstanding——60m61m88m92m95m106m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CRBU vs IRDCRBU vs RLAYCRBU vs HYFT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Caribou Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Caribou Biosciences, Inc.